Tiumbio Kosdaq News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Tiumbio Kosdaq. Real-time updates on events, politics, business and more.

TiumBio Presents Phase 1b Interim Results for TU2218 in Combination with Pembrolizumab at ASCO 2024 Annual Meeting

June 1, 2024

/PRNewswire/ -- TiumBio Co., Ltd. (Kosdaq: 321550), a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics...

United States South Korea Kyonggi Do Tiumbio Kosdaq Hun Taek Kim Suna Cho

Source: prnewswire.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Tiumbio Kosdaq News Today

TiumBio Presents Phase 1b Interim Results for TU2218 in Combination with Pembrolizumab at ASCO 2024 Annual Meeting

Explore More Categories